Add Formweb to your mobile device
System Formulary Update
Belimumab (Benlysta) Intravenous Injection
Situation
Belimumab (Benlysta) lyophilized powder for Intravenous Injection has been approved for addition to the UNC Health Medication Formulary.
Background
Benlysta is a human monoclonal antibody indicated to treat patients 5 years and older with active, autoantibody-positive systemic lupus erythematosus who are receiving standard therapy and adults with active lupus nephritis
who are receiving standard therapy. Benlysta is dosed at 10 mg/kg IV at 2-week intervals for the first 3 doses; followed by every 4 weeks thereafter.
It was reviewed by the System P&T Committee in July 2022 for formulary addition.
Assessment/Recommendations
The P&T Committee voted to APPROVE the addition of Benlysta to System Formulary WITH RESTRICTION to the following:
- Inpatient use restricted to new starts for patients with active lupus nephritis
- All other use is restricted to outpatient/clinic us only
Formulary/Epic changes will Go-Live on Tuesday, September 13, 2022.